How do we optimize the clinical benefit of our current treatment regimens and what strategies do you recommend for making patients more adherent and improving tolerability of medications used for MAC lung disease?

How do we optimize the clinical benefit of our current treatment regimens and what strategies do you recommend for making patients more adherent and improving tolerability of medications used for MAC lung disease?

How do we optimize the clinical benefit of our current treatment regimens and what strategies do you recommend for making patients more adherent and improving tolerability of medications used for MAC lung disease?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina